11 June 2018

Designing and Monitoring Anti-NGF Imaging Endpoints

Written by Colin G. Miller



Anti-nerve growth factor (NGF) therapeutics are a new class of powerful analgesics in clinical development. But the FDA put their clinical development on hold in 2012 because joint destruction was observed in a small subset of patients. Pfizer, the leading developer of NGF compounds, needed a way to evaluate all major joints in subjects entering the new Phase III program.


Members of our group have substantial experience in imaging in osteoarthritis and NGF-targeting therapies affected joints in a similar manner, so Pfizer specifically sought us out. The solution was to:

  • Engage a team of radiologists to develop a new radiographic technique to evaluate the joints in the defined patient population.

  • Build and participate in a strong academic team that published a landmark Imaging Atlas in 2015. The book described the technique and now serves as a key clinical reference.

  • Further develop specific inter-reader training and validation techniques to reduce variability in this new arena.  The first reproducibility paper from this study has already been published.


Pfizer conducted a very successful anti-NGF program with all the radiological and MRI reads done in a reproducible and effective manner.


Developing and Executing a Campaign to Boost Web Traffic by 85%

Case Study Highlights 85% increase in overall users to the client’s website 92% increase in new..

Providing Agile Regulatory Expertise for Teams Temporarily Under Resourced

Finding, securing, and retaining the top talent required to be an integral part of drug development..